Research News and Research

RSS

Geron 2010 third quarter revenue increases from $494,000 to $546,000

Geron Corporation today reported financial results for the three and nine months ended September 30, 2010.

29 Oct 2010

ImmunoGen first quarter net loss increases to $12.9 million

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended September 30, 2010 - the first quarter of the Company's 2011 fiscal year (1QFY11).

29 Oct 2010

Statewatch: D.C poised to approve Johns Hopkins-Sibley deal; Controversial Medicaid cuts in Idaho, Indiana

The Washington Post: "The agreement for Baltimore-based Johns Hopkins Health System to acquire Sibley Memorial Hospital is likely to be approved by District officials as soon as Thursday, giving the world-class academic medical center its first foothold in the District. Driven by Sibley's need to ensure long-term financial stability by increasing its volume of patients, the move will allow Hopkins to improve its market position in the Washington-Baltimore region.

29 Oct 2010

Latuda tablets receive FDA approval for treatment of adults with schizophrenia

The U.S. Food and Drug Administration today approved Latuda (lurasidone HCl) tablets for the treatment of adults with schizophrenia.

29 Oct 2010

KHN Column: What if the President had changed his priorities? A pre-election analysis from an alternate universe

In his latest Kaiser Health News column, done in collaboration with The New Republic, Jonathan Cohn writes, Mere days stand between the Democrats and a major defeat at the polls.

29 Oct 2010

Pain Therapeutics third quarter net loss decreases from $1.3 million to $1.0 million

Pain Therapeutics, Inc. a biopharmaceutical company, today reported financial results for its third quarter of fiscal year 2010.

29 Oct 2010

Health on The Hill – October 27, 2010

Kaiser Health News staff writer Mary Agnes Carey talks with The Fiscal Times' Eric Pianin and KFF's Jackie Judd about the latest news in politics and health policy.

29 Oct 2010

Neurocrine third quarter revenue increases from $0.7 million to $14.4 million

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended September 30, 2010.

29 Oct 2010

Opinions: Defense, diplomacy, development; PMTCT in Africa; perils of DIY aid; cholera in Haiti

In a Foreign Affairs essay, Secretary of State Hillary Rodham Clinton writes of the need to elevate diplomacy and development alongside defense a 'smart power' approach to solving global problems.

29 Oct 2010

Gen-Probe third quarter research revenue increases 70% to $3.4 million

Gen-Probe Incorporated today reported financial results for the third quarter of 2010, highlighted by 19% growth in non-GAAP earnings per share (EPS) and 8% growth in product sales and total revenues.

29 Oct 2010

Today's Op-Eds: Medicare rip-offs; Courts and the individual mandate; Accountable care

Instead of getting hung up on labels adopted in the heat of political battle, they should focus instead on Supreme Court precedents that found that taxes designed to influence behavior, like taxes to deter the sale of particularly dangerous firearms, were constitutional, provided they raised revenue in the process.

29 Oct 2010

Tenofovir gel to prevent HIV transmission nearing approval

Anti HIV drug Tenofovir in its gel form is to be fast-tracked for approval by the US FDA. The announcement was made by Conrad, a nonprofit scientific organization based in Arlington, Virginia that works with reproductive health.

28 Oct 2010

Slivers of frozen ovaries allow for childbirth later in life

According a US fertility expert, young women should freeze parts of their ovaries if they want to postpone motherhood until later in life. This advice came from Dr Sherman Silber at the American Society for Reproductive Medicine meeting in Denver.

28 Oct 2010

Chillies for diabetes: Study

Researchers from Tasmania, Australia are recruiting volunteers in a study to explore if eating chillies can help control lifestyle-related diabetes. At present they need 35 people with type 2 diabetes or glucose intolerance.

28 Oct 2010

Metagenics awarded two new patents for hops-derived anti-inflammatory compositions

Metagenics, Inc. has been awarded two new patents for discoveries relating to its research on the anti-inflammatory properties of reduced iso-alpha acids (RIAA) derived from hops. Metagenics is a life sciences company focused on reversing chronic illness and improving health through therapeutic nutrition and lifestyle changes. The discoveries were made by researchers at Metagenics’ wholly-owned biotechnology subsidiary, MetaProteomics® LLC.

28 Oct 2010

Common psychiatric drugs could slow dementia

Researchers say commonly used psychiatric drugs could be effective in slowing the progression of certain types of dementia. Dr John Kwok and colleagues from Neuroscience Research Australia have discovered a mutant gene that causes abnormal proteins build up in the brains of people with frontotemporal dementia, a disease that affects people in their 50s and 60s.

28 Oct 2010

Malvern Zetasizer Nano used to characterize environmentally responsive nanoparticles

The rapid, real-time measurement capabilities of the Zetasizer Nano system from Malvern Panalytical have enabled quantified nanoscale characterization of the environmental sensitivity of novel solubilization nanoparticles.

From Malvern Panalytical 28 Oct 2010

Bioniche ranked #14 on Top 50 Best Small and Medium Employers in Canada

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, is pleased to be named among the Top 50 Best Small and Medium Employers in Canada. Bioniche was ranked number 14 by its employees. Two years ago, the Company attained a 13th place ranking.

28 Oct 2010

Encision second quarter net sales decrease 11% to $2.87 million

Encision Inc., a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, reported its financial results for its second fiscal quarter ended September 30, 2010.

28 Oct 2010

Caliper Life Sciences third quarter GAAP revenue decreases 8% to $29.7 million

Caliper Life Sciences, Inc., today reported results for its third quarter ended September 30, 2010. Third quarter GAAP revenue decreased 8% to $29.7 million from $32.2 million in the same period in 2009 as a result of divestitures in 2010 and 2009. Revenue from on-going business increased 10% on a reported basis and 11% on an organic basis.

28 Oct 2010

Research News and Research

Geron 2010 third quarter revenue increases from $494,000 to $546,000

ImmunoGen first quarter net loss increases to $12.9 million

Statewatch: D.C poised to approve Johns Hopkins-Sibley deal; Controversial Medicaid cuts in Idaho, Indiana

Latuda tablets receive FDA approval for treatment of adults with schizophrenia

KHN Column: What if the President had changed his priorities? A pre-election analysis from an alternate universe

Pain Therapeutics third quarter net loss decreases from $1.3 million to $1.0 million

Health on The Hill – October 27, 2010

Neurocrine third quarter revenue increases from $0.7 million to $14.4 million

Opinions: Defense, diplomacy, development; PMTCT in Africa; perils of DIY aid; cholera in Haiti

Gen-Probe third quarter research revenue increases 70% to $3.4 million

Today's Op-Eds: Medicare rip-offs; Courts and the individual mandate; Accountable care

Tenofovir gel to prevent HIV transmission nearing approval

Slivers of frozen ovaries allow for childbirth later in life

Chillies for diabetes: Study

Metagenics awarded two new patents for hops-derived anti-inflammatory compositions

Common psychiatric drugs could slow dementia

Malvern Zetasizer Nano used to characterize environmentally responsive nanoparticles

Bioniche ranked #14 on Top 50 Best Small and Medium Employers in Canada

Encision second quarter net sales decrease 11% to $2.87 million

Caliper Life Sciences third quarter GAAP revenue decreases 8% to $29.7 million

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News